Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Aug 07, 2026
TSLQ Delivers +65% Gains as TSLA Slides on Q2 Miss: An Inverse ETF Breakdown

TSLQ Delivers +65% Gains as TSLA Slides on Q2 Miss: An Inverse ETF Breakdown

Key Takeaways

  • TSLQ surged approximately 65% over the trailing 30-day period, driven by a sharp decline in TSLA shares following Tesla's Q2 2026 earnings report.
  • Tesla's stock dropped roughly 27% over the same window, and TSLQ's -2x daily leveraged structure amplified those losses into outsized gains for inverse ETF holders.
  • The primary catalyst was a significant earnings miss: Tesla reported adjusted EPS of $0.33 versus consensus estimates near $0.51, while operating margin collapsed to 1.4%.
  • Over the broader quarter, TSLQ gained approximately 23%, reflecting a more mixed period before the concentrated July selloff in TSLA.
  • As a leveraged inverse single-stock ETF, TSLQ is structured for short-term tactical trading and is not intended as a buy-and-hold vehicle due to the effects of daily compounding.

Tradr 2X Short TSLA Daily ETF (TSLQ) Overview and Portfolio Exposure

The Tradr 2X Short TSLA Daily ETF (TSLQ) is an actively managed exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to two times the inverse (-200%) of the daily performance of Tesla, Inc. (TSLA) common shares. Issued by AXS Investments and launched in July 2022, the fund maintains at least 80% exposure to financial instruments — primarily total return swaps and contracts for difference (CFDs) — that deliver inverse leveraged exposure to TSLA on a single-day basis.

TSLQ carries a net expense ratio of 1.15% and held approximately $116 million in assets under management (AUM — the total market value of assets the fund manages). The portfolio is non-diversified and concentrated almost entirely around a single underlying equity: Tesla. The top holdings consist of swap agreements and CFDs referencing TSLA, alongside substantial cash and cash-equivalent positions that serve as collateral. Because TSLQ's performance is directly tied to the inverse daily movement of a single stock, its return profile is highly volatile and entirely dependent on TSLA's price direction. This concentrated structure explains why a sharp drawdown in Tesla shares translates so directly into amplified gains for TSLQ.

Tradr 2X Short TSLA Daily ETF (TSLQ) Price Performance: Last 30 Days vs. Quarter

Over the most recent 30-day period, TSLQ delivered an extraordinary gain of approximately 65%. The move was not gradual — it was concentrated and event-driven, with the bulk of the advance occurring in the final week of July when Tesla shares suffered one of their steepest single-day declines in history. Daily trading volume in TSLQ surged well above its three-month average during this period, reflecting intense tactical interest from traders positioning for or hedging against further TSLA weakness.

Over the broader quarter, TSLQ gained roughly 23%. This more modest three-month return reflects a divergent pattern: during April and May, TSLA shares were relatively resilient, which kept TSLQ range-bound and at times under pressure. The fund's quarterly gain is almost entirely attributable to the July selloff in TSLA. The contrast between the 30-day and quarterly figures illustrates how quickly leveraged inverse products can reverse course when the underlying equity enters a pronounced trend.

What Drove TSLQ Price in the Last 30 Days

The overwhelming driver of TSLQ's 30-day surge was Tesla's second-quarter 2026 earnings report, released after the market close on July 22. Despite record quarterly deliveries of 480,126 vehicles and revenue of $28.24 billion that exceeded consensus estimates, profitability metrics deteriorated sharply. Adjusted earnings per share (EPS — the portion of a company's profit allocated to each outstanding share) came in at $0.33, roughly 35% to 39% below analyst expectations of $0.51 to $0.54. GAAP operating income fell 57% year-over-year to $398 million, producing an operating margin of just 1.4%.

Several additional factors compounded the negative sentiment. Tesla's gross margin contracted to 16.8%, well below the consensus forecast of approximately 19.4%, as the company's mix shifted toward lower-priced vehicle variants and away from discontinued higher-margin Model S and Model X units. Capital expenditures (CapEx — funds used to acquire or upgrade physical assets) nearly doubled sequentially to $5.8 billion, pushing free cash flow (FCF — operating cash flow minus capital expenditures) to negative $1.1 billion. Management reaffirmed full-year CapEx guidance above $25 billion, with spending expected to increase further in subsequent years to fund AI infrastructure, Robotaxi expansion, and Optimus humanoid robot production.

The market reaction was swift and severe. TSLA shares fell as much as 15% intraday on July 23, erasing more than $140 billion in market capitalization in a single session. With the stock closing near $320 that day and continuing to slide toward $309 by month-end, TSLQ's -2x daily leverage mechanically amplified those declines into substantial gains. The fund's performance was further supported by sustained elevated trading volumes and a broader rotation away from high-valuation, high-CapEx technology names as investors reassessed the near-term payoff profile of aggressive AI spending.

What Drove TSLQ Performance Over the Last Quarter

The quarterly picture is more nuanced. During April and the first half of May, TSLA shares traded within a relatively stable range, buoyed by optimism around delivery growth, Full Self-Driving subscription momentum, and the launch of unsupervised Robotaxi services in select U.S. cities. During this phase, TSLQ drifted lower or traded sideways, reflecting the inverse relationship. By late June, TSLA had recovered toward the $420 level, and TSLQ had declined to approximately $16–$17.

The turning point arrived with the Q2 earnings release. The quarterly gain of roughly 23% for TSLQ therefore masks considerable intra-quarter volatility: a challenging environment for inverse strategies during the first two months, followed by a concentrated July rally that more than recovered earlier losses. This pattern underscores an important structural feature of leveraged inverse ETFs: their returns over periods longer than a single day are path-dependent and can diverge meaningfully from a simple multiple of the underlying asset's cumulative return due to the mathematics of daily compounding. The divergence was favorable for TSLQ holders in this instance because TSLA's decline was sharp and sustained.

TSLQ ETF Outlook: What Investors Should Watch Next

The forward-looking environment for TSLQ remains closely tied to Tesla's ability to stabilize profitability while executing on its ambitious capital investment roadmap. Investors should monitor several key factors in the months ahead. First, Tesla's automotive gross margin trajectory will be critical — any recovery toward the 19–20% range could stabilize TSLA shares and pressure inverse positions. Second, CapEx spending levels and free cash flow generation will remain under intense scrutiny; another quarter of significant cash burn could extend Tesla's decline. Third, progress on Robotaxi deployment, FSD subscription growth, and Optimus commercialization will influence whether the market continues assigning a premium technology multiple to a company whose core auto business currently operates at a 1.4% margin.

Macroeconomic conditions also matter. The Federal Reserve's interest rate path affects growth-stock valuations broadly, and any shift in rate expectations could impact TSLA's multiple. Additionally, the competitive landscape in electric vehicles continues to intensify, with legacy automakers and Chinese manufacturers pressing on pricing. On the fund-specific level, TSLQ's daily reset mechanism means that its performance will depend not only on the direction of TSLA shares but also on the path they take — periods of choppy, range-bound trading can erode returns in leveraged inverse products even if the underlying stock ends the period modestly lower. Finally, elevated volatility in single-stock leveraged ETFs makes position sizing and risk management essential considerations for any investor using these instruments.

AI-Powered Screening in My Research Process

When evaluating leveraged products like TSLQ or comparing them against sector peers, I often turn to Tickeron’s AI Screener to quickly filter for volatility, technical patterns, and industry signals that align with the trade thesis. It streamlines the process of spotting comparable opportunities without manually sifting through thousands of securities.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TSLQ

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


TSLQ in upward trend: price rose above 50-day moving average on July 16, 2026

TSLQ moved above its 50-day moving average on July 16, 2026 date and that indicates a change from a downward trend to an upward trend. In of 31 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for TSLQ crossed bullishly above the 50-day moving average on July 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TSLQ advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 141 cases where TSLQ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for TSLQ moved out of overbought territory on July 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TSLQ as a result. In of 70 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for TSLQ turned negative on August 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSLQ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TSLQ broke above its upper Bollinger Band on July 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-200%) of the daily performance of the common shares of TSLA. Under normal market circumstances, the fund will maintain at least 80% exposure to financial instruments that provide inverse exposure to two times the daily performance of TSLA. It is an actively-managed exchange-traded fund (“ETF”) that seeks to achieve on a daily basis, before fees and expenses, -200% performance of TSLA for a single day, not for any other period, by entering into one or more swaps on TSLA. The fund is non-diversified.
View a ticker or compare two or three
TSLQ
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Inverse Equity
Address
Investment Managers Series Trust II803 West Michigan StreetMilwaukee
Phone
(414) 299-2295
Web
N/A
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.